<DOC>
	<DOCNO>NCT03017950</DOCNO>
	<brief_summary>The purpose study examine compare pharmacokinetic drug interaction safety single administration combination administration CKD-330 D086 healthy male subject</brief_summary>
	<brief_title>Pharmacokinetic Drug-drug Interaction CKD-330 D086</brief_title>
	<detailed_description>An open-label , randomize , multiple-dose , 2-sequence , 2-period , 2-treatment , crossover study Part1 : Examining D086 affect pharmacokinetics CKD-330 . Part2 : Examining CKD-330 affect pharmacokinetics D086 .</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<criteria>1 . Healthy adult male age 19 45 day screen . 2 . Body mass index ( BMI ) 18.0 29.0 kg/m^2 weight ≥ 55kg ( Body mass index ( BMI ) = weight ( kg ) / height ( ) ^2 ) 3 . Subjects good health determine physical exam medical examination . No congenital chronic disease abnormal sign determine medical examination . 4 . Not abnormal clinically significant lab value . 5 . Subjects sign informed consent form good understanding explanation investigator . 1 . No history presence clinically significant cardiac , respiratory , neurological , endocrine , metal renal disease liver kidney disease . 2 . Subjects show angioedema adverse reaction ACE inhibitor 3 . Primary Hyperaldosteronism 4 . History family history myopathy 5 . Subjects mental disease drug addiction 6 . Allergic reaction candesartan amlodipine atorvastatin 7 . Genetic problem galactose intolerance , Lapp lactose deficiency , glucosegalactose malabsorption . 8 . Hypotension ( SBP ≤100mmHg DBP≤55mnHg ) hypertension ( SNP ≥ 150mmHg , DBP ≥95mmHg ) day screen 9 . Subjects experience gastrointestinal disease surgery affect absorption Investigational product 10 . Subjects abnormal lab value least one ( AST ALT &gt; 2 fold upper normal limit , Total bilirubin &gt; 2 fold upper normal limit , CPK &gt; 2 fold upper normal limit , K &lt; 3.5mEq/L &gt; 5.5mEq/L , Estimated Glomerular filtration rate &lt; 60mL/min/1.73m2 Modification ) 11 . Continuous drinking ( 21 units/week , 1 unit= 10g=12.5mL pure alcohol ) , heavy smoker ( &gt; 10 cigarette per day ) unable stop drinking clinical trial 12 . Subjects previously participate clinical trial within 90 day 13 . Subjects donate whole blood within 60 day donate component blood within 30 day receive blood transfusion within 30 day 14 . Subjects administer medication within 30 day ( cyclosporin , erythromycin , clarithromycin , lopinavir , ritonavir , itraconazole , ketoconazole , rifampicin , barbiturate : thesis medicine could affect absorption , metabolism , distribution excretion candesartan , amlodipine atorvastatin ) 15 . Subjects take prescribed medication oriental medicine within 14 day , take pharmacy medicine within 7 day . 16 . Subjects take diet affect absorption , metabolism , distribution excretion investigational product ( especially grapefruit juice ) . 17 . Subjects condition impossible participate clinical trial follow laboratory test . 18 . Unable use contraception .</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>